Literature DB >> 16963548

Guidelines for chronic obstructive pulmonary disease treatment and issues of implementation.

Klaus F Rabe1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Treatment advances over the last decade, although limited, have precipitated the development of clinical practice guidelines, with the aim of improving the quality of care received by patients through fostering evidence-based decision making and accelerating the application of new advances to everyday practice. Of the COPD guidelines that have been developed, those developed through the Global Initiative for Chronic Obstructive Lung Disease (GOLD), initially a joint activity between the U.S. National Heart, Lung, and Blood Institute and the World Health Organization, and the National Institute of Clinical Excellence (NICE) in the United Kingdom have both published their methods for evaluation of evidence. These comprehensive guidelines cover all aspects of the disease, with the aim of providing the basis for local care pathways. The guideline development process includes evaluation of the evidence, development of the guideline, and dissemination of the findings. Efforts to enhance guideline effectiveness have focused on improving the methods and approaches to implementation, which requires an appreciation of the issues that stop translation of guideline definitions of best practice into improved patient care. A variety of questions remain unanswered in the clinical management of COPD, including the definition of outcome measures that move beyond lung function, the potential application of multidimensional grading systems that assess respiratory and systemic expressions of COPD and that could possibly better categorize and predict outcome in these patients, and the impact of new clinical trial findings. Large ongoing outcome studies may also have an effect on defining best practice within future guideline recommendations.

Entities:  

Mesh:

Year:  2006        PMID: 16963548     DOI: 10.1513/pats.200604-099SS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  8 in total

1.  The Effect of a Short Duration, High Intensity Exercise Intervention on Gait Biomechanics in Patients With COPD: Findings From a Pilot Study.

Authors:  Jennifer M Yentes; Daniel Blanke; Stephen I Rennard; Nicholas Stergiou
Journal:  Chronic Obstr Pulm Dis       Date:  2014-05-06

2.  Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD.

Authors:  Joseph Seaman; Anthony C Leonard; Ralph J Panos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-04-07

3.  Clinical pharmacy-led disease and medicine management programme for patients with COPD.

Authors:  Maher R Khdour; Joseph C Kidney; Bronagh M Smyth; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

Review 4.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

5.  Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency.

Authors:  A-Rembert Koczulla; Danny Jonigk; Thomas Wolf; Christian Herr; Sarah Noeske; Walter Klepetko; Claus Vogelmeier; Nils von Neuhoff; Johanna Rische; Sabine Wrenger; Heiko Golpon; Robert Voswinckel; Maurizio Luisetti; Ilaria Ferrarotti; Tobias Welte; Sabina Janciauskiene
Journal:  Orphanet J Rare Dis       Date:  2012-05-23       Impact factor: 4.123

6.  Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database.

Authors:  David P Miller; Stephanie E Watkins; Tim Sampson; Kourtney J Davis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-09-16

7.  Failed upregulation of TFAM protein and mitochondrial DNA in oxidatively deficient fibers of chronic obstructive pulmonary disease locomotor muscle.

Authors:  Yana Konokhova; Sally Spendiff; R Thomas Jagoe; Sudhakar Aare; Sophia Kapchinsky; Norah J MacMillan; Paul Rozakis; Martin Picard; Mylène Aubertin-Leheudre; Charlotte H Pion; Jean Bourbeau; Russell T Hepple; Tanja Taivassalo
Journal:  Skelet Muscle       Date:  2016-02-18       Impact factor: 4.912

8.  The effect of an active implementation of a disease management programme for chronic obstructive pulmonary disease on healthcare utilization--a cluster-randomised controlled trial.

Authors:  Margrethe Smidth; Morten Bondo Christensen; Morten Fenger-Grøn; Frede Olesen; Peter Vedsted
Journal:  BMC Health Serv Res       Date:  2013-10-03       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.